Double-blind, randomized, phase III clinical trial to evaluate the immunogenicity and reactogenicity of three consecutive doses of diphtheria tetanus pertussis acellular (dTpa), or of dTpa-IPV followed by two doses of Td vaccine, and compared to three consecutive doses of Td vaccine administered to healthy adults in a 0, 1, 6-month schedule

Trial Profile

Double-blind, randomized, phase III clinical trial to evaluate the immunogenicity and reactogenicity of three consecutive doses of diphtheria tetanus pertussis acellular (dTpa), or of dTpa-IPV followed by two doses of Td vaccine, and compared to three consecutive doses of Td vaccine administered to healthy adults in a 0, 1, 6-month schedule

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2006

At a glance

  • Drugs Diphtheria-tetanus vaccine; DTaP poliovirus vaccine; DTaP vaccine
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top